Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.
Breast cancer, the second most common cancer in women, exerts a multidimensional grave effect on affected women. Among the several subtypes of breast cancer, the overexpression of the human epidermal growth factor receptor-2 gene is associated with poorer survival and higher relapse rates. Trastuzumab, a monoclonal antibody, has proved its safety and efficacy in this specific subtype, nevertheless its high cost urges for caution among payers. The scope of this study is to systematically search and critically assess the economic evaluation studies of trastuzumab in patients with early stage Her2+ breast cancer. In the majority of the studies, trastuzumab was found to be cost-effective. Its cost-effectiveness profile is contingent to treatment duration, benefit effect, and age of the patient.